KIORA PHARMACEUTICALS, INC. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
KIORA PHARMACEUTICALS, INC. (KPRX) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2025-03-25
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2023-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2023-09-30 was $530.99K.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2023 was $530.99K.
- KIORA PHARMACEUTICALS, INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2022 was $0.00.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $530.99K derived: sum of 2 quarters · filed 2025-03-25 | $530.99K 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $530.99K 10-Q · filed 2024-11-08 | $530.99K 10-Q · filed 2024-11-08 | |||
| 2023-08-07 | $500.00K 10-K · filed 2025-03-25 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |